Yet, in the past decade, preclinical evidence suggested that RANKL/RANK pathway inhibition could be a potential strategy to improve the effectiveness of immune checkpoint inhibitors (ICI) in cancer treatment [125]. The gene discussed is TNFSF11; the disease is cancer.